In leukemia, this drug induces mitotic catastrophe in chronic myelogenous leukemia (CML) cells via JNK-dependent inhibition of Plk1 expression and triggers apoptosis by a caspase 2-mediated mechanism (Dufies et al., 2011). The gene discussed is CASP2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.